Professor Peter Schmid

Clinical Director, Breast Cancer Centre, St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital
Professor Peter Schmid

Professor Peter Schmid

Clinical Director, Breast Cancer Centre, St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital
Back

Biography

Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre. He leads the academic breast cancer programmes and the cancer immune therapy group at Barts Cancer Institute.

Professor Schmid trained in medicine at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded scholarships by the ‘Studienstiftung des deutschen Volkes’, the ‘Hanns-Seidel-Foundation’, and the ‘Deutscher Akademischer Austauschdienst’. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich. He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University in Berlin in 2005 and was awarded the “habilitation and venia legendi” and an external readership by the Charité University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex University Hospitals until his move to Barts.

Professor Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour DNA.

Professor Schmid is a member of several national and international cancer organizations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 165 publications and has published a book on the management of bone metastases (3rd edition).

Sessions by Professor Peter Schmid

Session 1: Highlights of 2017

09:10-10:30
Exchange Auditorium